Risk factors

Rein Therapeutics (RNTX) risk factors

Item 1A of every Rein Therapeutics, Inc. 10-K on file, and what changed from one year to the next.

Open RNTX in Gloomberb →
  • FY2025 10-K risk factors

    76 risks, 8 new, 31 dropped, 14 reworded since the prior year. Rein Therapeutics faces going concern doubts after reporting a $50.6 million operating loss in 2025 and an accumulated deficit of $401.3 million. The company indefinite paused development of product candidate LTI-01 due to capital limitations, increasing reliance on lead candidate LTI-03. Macroeconomic pressures include a 10% tariff on imports from China announced in February 2025.

    Filed Mar 26, 2026
  • FY2024 10-K risk factors

    99 risks. Clinical-stage biopharmaceutical company focusing on fibrosis treatments LTI-03 and LTI-01.

    Filed Apr 07, 2025